Glaxo Imitrex nasal spray will be launched with wholesale acquisition cost of $14.80 per dose.
Executive Summary
GLAXO IMITREX NASAL SPRAY SET FOR OCTOBER LAUNCH following FDA approval Aug. 26, the company said. The wholesale acquisition cost of the intranasal migraine therapy will be $14.80 per dose, according to Glaxo Wellcome. The supplemental NDA for the intranasal formulation of sumatriptan (20-626) was submitted on Aug. 29, 1995, and became "approvable" on April 23.